RARE missed EPS expectations by 5.62%
Feb 13, 2025, 11:35 PM
0.00%
What does RARE do
Ultragenyx Pharmaceutical, based in Novato, California, focuses on developing therapies for rare genetic diseases and has four approved products, including Crysvita and Mepsevii. The company went public on January 31, 2014, and employs 1,276 people.
Ultragenyx Pharmaceutical (RARE) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Ultragenyx Pharmaceutical's actual EPS was -$1.39, missing the estimate of -$1.32 per share, resulting in a -5.62% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.